IL259711B - Protein kinase inhibitor, preparation method and medical use thereof - Google Patents

Protein kinase inhibitor, preparation method and medical use thereof

Info

Publication number
IL259711B
IL259711B IL259711A IL25971118A IL259711B IL 259711 B IL259711 B IL 259711B IL 259711 A IL259711 A IL 259711A IL 25971118 A IL25971118 A IL 25971118A IL 259711 B IL259711 B IL 259711B
Authority
IL
Israel
Prior art keywords
compound
compound according
alkyl
hydrogen atom
fluoro
Prior art date
Application number
IL259711A
Other languages
English (en)
Hebrew (he)
Other versions
IL259711A (en
Inventor
Lei Yin
Wenjian Liu
Heng Li
Dianxi Zhu
Original Assignee
Gan& Lee Pharmaceuticals
Lei Yin
Wenjian Liu
Heng Li
Dianxi Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58796287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL259711(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gan& Lee Pharmaceuticals, Lei Yin, Wenjian Liu, Heng Li, Dianxi Zhu filed Critical Gan& Lee Pharmaceuticals
Publication of IL259711A publication Critical patent/IL259711A/en
Publication of IL259711B publication Critical patent/IL259711B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
IL259711A 2015-11-30 2016-11-28 Protein kinase inhibitor, preparation method and medical use thereof IL259711B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510856641.1A CN106810536A (zh) 2015-11-30 2015-11-30 一种蛋白激酶抑制剂及其制备方法和医药用途
PCT/CN2016/107455 WO2017092635A1 (zh) 2015-11-30 2016-11-28 一种蛋白激酶抑制剂及其制备方法和医药用途

Publications (2)

Publication Number Publication Date
IL259711A IL259711A (en) 2018-07-31
IL259711B true IL259711B (en) 2022-08-01

Family

ID=58796287

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259711A IL259711B (en) 2015-11-30 2016-11-28 Protein kinase inhibitor, preparation method and medical use thereof

Country Status (21)

Country Link
US (2) US11091476B2 (enExample)
EP (1) EP3385262B1 (enExample)
JP (2) JP6921101B2 (enExample)
KR (1) KR20180083421A (enExample)
CN (3) CN106810536A (enExample)
AU (1) AU2016365366B2 (enExample)
BR (1) BR112018010879A2 (enExample)
CA (1) CA3002884A1 (enExample)
CO (1) CO2018005854A2 (enExample)
DK (1) DK3385262T3 (enExample)
ES (1) ES2928169T3 (enExample)
HU (1) HUE060152T2 (enExample)
IL (1) IL259711B (enExample)
MA (1) MA42341B2 (enExample)
MX (1) MX387207B (enExample)
PH (1) PH12018550049A1 (enExample)
PT (1) PT3385262T (enExample)
RU (1) RU2749437C2 (enExample)
UA (1) UA124001C2 (enExample)
WO (1) WO2017092635A1 (enExample)
ZA (1) ZA201803531B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) * 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
US11440912B2 (en) 2017-10-27 2022-09-13 Fresenius Kabi Oncology Ltd Process for the preparation of ribociclib and its salts
BR112020015431A2 (pt) 2018-02-15 2020-12-08 Nuvation Bio Inc. Compostos heterocíclicos como inibidores de quinase
WO2019170055A1 (zh) * 2018-03-05 2019-09-12 上海海和药物研究开发有限公司 具有cdk4/6激酶抑制活性的化合物、其药用组合物和用途
SG11202108004VA (en) * 2019-01-29 2021-08-30 Beta Pharma Inc 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases
EP3988545A1 (en) * 2019-06-21 2022-04-27 Gan & Lee Pharmaceuticals Co., Ltd. Methods for preparing cdk4/6 inhibitor and salt and intermediate thereof
AR119184A1 (es) * 2019-06-21 2021-12-01 Gan & Lee Pharmaceuticals Sales de un compuesto, formas cristalinas de las sales y método de preparación y uso de las mismas
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
CN116583283A (zh) * 2020-09-21 2023-08-11 普莱鲁德疗法有限公司 Cdk抑制剂及其作为药物的用途
US12129262B2 (en) 2020-12-18 2024-10-29 Prelude Therapeutics Incorporated CDK inhibitors and their use as pharmaceuticals
CN112390793B (zh) * 2021-01-19 2021-04-27 中国药科大学 Cdk6/dyrk2双靶点抑制剂及其制备方法和应用
WO2022218247A1 (zh) * 2021-04-12 2022-10-20 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物
WO2022242563A1 (zh) * 2021-05-17 2022-11-24 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
WO2023040914A1 (zh) * 2021-09-14 2023-03-23 甘李药业股份有限公司 一种cdk4/6抑制剂的医药用途
CN118339157A (zh) * 2021-12-24 2024-07-12 江苏恒瑞医药股份有限公司 氢化吲哚类化合物、其制备方法及其在医药上的应用
CN115093397B (zh) * 2022-06-07 2023-09-05 自贡市第三人民医院 一种用于治疗肿瘤的化合物、合成方法及应用
CN117658987A (zh) * 2022-09-08 2024-03-08 上海深势唯思科技有限责任公司 作为plk1抑制剂的化合物及其制备方法和用途
CN119790049A (zh) * 2022-09-30 2025-04-08 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264725A (zh) * 2008-12-22 2011-11-30 伊莱利利公司 蛋白激酶抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
SK12712002A3 (sk) 2000-02-07 2003-02-04 Abbott Gmbh & Co. Kg Deriváty 2-benzotiazolylmočoviny a ich použitie ako inhibítorov proteínkináz
MEP46108A (en) * 2002-01-22 2011-02-10 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
WO2005076854A2 (en) * 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
WO2008124085A2 (en) * 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2715658C (en) * 2008-02-15 2016-07-19 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
RU2504545C2 (ru) 2008-05-16 2014-01-20 Ф. Хоффманн-Ля Рош Аг Ингибиторы jnk
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN106608879A (zh) 2015-10-27 2017-05-03 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
EP3679043B9 (en) 2017-09-05 2023-09-27 Neumora Therapeutics, Inc. Vasopressin receptor antagonists and products and methods related thereto
WO2022218247A1 (zh) 2021-04-12 2022-10-20 甘李药业股份有限公司 作为cdk4/6抑制剂的氘代化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264725A (zh) * 2008-12-22 2011-11-30 伊莱利利公司 蛋白激酶抑制剂

Also Published As

Publication number Publication date
US11091476B2 (en) 2021-08-17
JP6921101B2 (ja) 2021-08-18
ZA201803531B (en) 2021-10-27
KR20180083421A (ko) 2018-07-20
RU2749437C2 (ru) 2021-06-10
MX387207B (es) 2025-03-18
UA124001C2 (uk) 2021-07-07
US20210371418A1 (en) 2021-12-02
JP2019500413A (ja) 2019-01-10
EP3385262A4 (en) 2019-06-19
ES2928169T3 (es) 2022-11-15
JP2021138737A (ja) 2021-09-16
CN108290864B (zh) 2022-05-10
HUE060152T2 (hu) 2023-02-28
MA42341B2 (fr) 2021-05-31
PT3385262T (pt) 2022-10-18
DK3385262T3 (da) 2022-10-10
AU2016365366A1 (en) 2018-05-17
MA42341A1 (fr) 2018-06-29
CN108290864A (zh) 2018-07-17
MX2018006370A (es) 2018-09-24
CN106810536A (zh) 2017-06-09
RU2018122864A (ru) 2020-01-13
CO2018005854A2 (es) 2018-06-20
US20200165239A1 (en) 2020-05-28
EP3385262B1 (en) 2022-07-13
EP3385262A1 (en) 2018-10-10
CN113956238B (zh) 2023-07-14
CA3002884A1 (en) 2017-06-08
IL259711A (en) 2018-07-31
BR112018010879A2 (pt) 2018-11-21
AU2016365366B2 (en) 2021-03-04
CN113956238A (zh) 2022-01-21
RU2018122864A3 (enExample) 2020-03-17
WO2017092635A1 (zh) 2017-06-08
PH12018550049A1 (en) 2018-10-29
US11787801B2 (en) 2023-10-17

Similar Documents

Publication Publication Date Title
US11787801B2 (en) Protein kinase inhibitors, preparation method and medical use thereof
JP2019500413A5 (enExample)
TWI642667B (zh) 吡啶並嘧啶類衍生物、其製備方法及其在醫藥上的應用
JP2020502065A (ja) ８，９−ジヒドロイミダゾール［１，２−ａ］ピリミド［５，４−ｅ］ピリミジン−５（６Ｈ）−ケトン類化合物
JP2024531477A (ja) Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用
AU2019316858B2 (en) Smad3 inhibitors
CN110914277B (zh) 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
KR101739003B1 (ko) 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
JP2020504139A (ja) キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途
EP3556761A1 (en) Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof
CN112457306A (zh) 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
KR20250080854A (ko) Pi3k 억제제로서의 이소퀴놀론
AU2017389818B2 (en) Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
CN117396208A (zh) 细胞周期蛋白依赖性激酶4/6(cdk4/6)和ikzf2(helios)的小分子降解剂及其使用方法
AU2017265769A1 (en) Novel 5H-Pyrrolo(2,3-D)Pyrimidin-6(7H)-one derivative
WO2024083237A1 (en) Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof
TW202237101A (zh) Ｃｔｌａ－４小分子降解劑及其應用
HK1260629A1 (en) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-amine derivatives as protein kinase inhibitors, preparation method and medical use thereof
HK1260629B (en) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-amine derivatives as protein kinase inhibitors, preparation method and medical use thereof
WO2022262671A1 (zh) 杂环大环化合物及其医药用途
KR20240128040A (ko) 2 고리성 골격을 갖는 1h-피라졸-3-아민 유도체
KR20250154499A (ko) Parp 억제제로서의 치환된 질소-함유 트리시클릭 화합물 및 이의 용도
WO2021143821A1 (zh) 稠合杂芳基类衍生物、其制备方法及其在医药上的应用